NASDAQ:TVGN Tevogen Bio (TVGN) Stock Price, News & Analysis → Better than Bitcoin? The Biotech Stock with 46,751% Potential (From Behind the Markets) (Ad) Free TVGN Stock Alerts $1.00 +0.15 (+17.65%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$0.93▼$1.2050-Day Range$0.85▼$9.5152-Week Range$0.80▼$21.09Volume10.79 million shsAverage Volume1.12 million shsMarket Capitalization$15.82 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsFinancialsHeadlinesSEC FilingsSocial MediaStock AnalysisChartCompetitorsFinancialsHeadlinesSEC FilingsSocial Media Get Tevogen Bio alerts: Email Address Ad Behind the MarketsBetter than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>> About Tevogen Bio Stock (NASDAQ:TVGN)Tevogen Bio Holdings Inc. operates as a clinical-stage biotechnology company that develops off-the-shelf precision T cell therapeutics in virology, oncology, and neurology. Its lead investigational precision T cell product, TVGN 489, is designed to address the unmet need of acute-risk COVID-19 patients, as well as a subset of patients suffering from long COVID. The company is based in Warren, New Jersey.Read More TVGN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TVGN Stock News HeadlinesApril 27, 2024 | finanznachrichten.deTevogen Bio Inc: Tevogen Bio CEO Highlights Expected Reporting of a $94.9 Million Liability Elimination, AI Initiative, and Leadership AppointmentsApril 26, 2024 | globenewswire.comTevogen Bio CEO Highlights Expected Reporting of a $94.9 Million Liability Elimination, AI Initiative, and Leadership AppointmentsApril 27, 2024 | Behind the Markets (Ad)Better than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.April 26, 2024 | msn.comU.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.98%April 24, 2024 | americanbankingnews.comTevogen Bio (NASDAQ:TVGN) Stock Price Down 1.2%April 20, 2024 | morningstar.comTevogen Bio Holdings Inc TVGNApril 16, 2024 | msn.comLive Nation Entertainment, Groupon And Other Big Stocks Moving Lower In Tuesday's Pre-Market SessionApril 11, 2024 | finance.yahoo.comTevogen Bio’s Chief Scientific Officer Speaks on the Harnessing of Cytotoxic T Lymphocytes (CTLs) to Target CancersApril 27, 2024 | Behind the Markets (Ad)Better than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.April 11, 2024 | globenewswire.comTevogen Bio's Chief Scientific Officer Speaks on the Harnessing of Cytotoxic T Lymphocytes (CTLs) to Target CancersApril 5, 2024 | seekingalpha.comTVGN Tevogen Bio Holdings Inc.April 4, 2024 | investorplace.comWhy Is Tevogen Bio (TVGN) Stock Up 46% Today?April 3, 2024 | globenewswire.comTevogen Bio Appoints Tapan V Shah as Head of Investor Relations and Corporate DevelopmentMarch 28, 2024 | globenewswire.comTevogen Bio Reports Series A-1 Preferred Stock Investment at $10 Conversion PriceMarch 27, 2024 | globenewswire.comTevogen Bio Announces Series A-1 Preferred Stock InvestmentMarch 20, 2024 | businesswire.comTevogen Bio Reports Its Investigational SARS-CoV-2 Specific T Cell Therapy, TVGN-489, Retains Activity Against the Dominant JN.1 VariantFebruary 27, 2024 | businesswire.comMittul Mehta, Head of Tevogen's Artificial Intelligence Initiative Tevogen.ai, Emphasizes Importance of Proactive Talent Development for Biopharmaceutical Sector to Allow Rapid Adoption of AIFebruary 21, 2024 | businesswire.comCell Therapy Company Tevogen Bio Holdings Inc. Prepares to Launch Crucial Genetic Predisposition Study in Preparation to Investigate the Potential of TVGN 489 to Address Critical Unmet Need for Long COVID TreatmentFebruary 17, 2024 | businesswire.comCell Therapy Company Tevogen Bio Holdings Inc. (Nasdaq: TVGN) Rings Opening Bell at Nasdaq Exchange on February 15th, 2024, Begins Public Trading on the Open MarketFebruary 15, 2024 | businesswire.comTevogen Bio Announces $8 Million Equity InvestmentFebruary 14, 2024 | globenewswire.comTevogen Bio Holdings Inc., a Cell Therapy Company, Announces Completion of Business Combination and is to be Listed on Nasdaq Under Ticker TVGNSee More Headlines Receive TVGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tevogen Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/27/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:TVGN Previous SymbolNASDAQ:TVGN CUSIPN/A CIK1860871 Webwww.semperparatusspac.com Phone913-579-4170FaxN/AEmployees17Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$4.41 million Net MarginsN/A Pretax MarginN/A Return on Equity-21.83% Return on Assets3.10% Debt Debt-to-Equity RatioN/A Current Ratio0.22 Quick Ratio0.22 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash Flow$0.39 per share Price / Cash Flow2.59 Book Value($1.10) per share Price / Book-0.91Miscellaneous Outstanding Shares15,820,000Free Float6,864,000Market Cap$15.82 million OptionableN/A Beta0.06 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesDr. Ryan H. Saadi M.D.M.P.H, M.P.H., Co-Founder, CEO & ChairmanMr. Kirti DesaiCFO & DirectorMr. Stephen Chen M.B.A.Chief Technical OfficerDr. Neal Flomenberg M.D.Chief Scientific Officer, Global R&D Lead & Chairman of Corporate BoardMr. Mittul MehtaChief Information Officer & Head of Tevogen.aiMr. Tapan V. ShahHead of Investor Relations & Corporate DevelopmentMr. Jeffrey Feike M.P.H.Chief Patient Officer, Member of Innovation & Public Health Advisory Council & DirectorMr. Sadiq KhanChief Commercial OfficerMore ExecutivesKey CompetitorsProtara TherapeuticsNASDAQ:TARAMiNK TherapeuticsNASDAQ:INKTAchilles TherapeuticsNASDAQ:ACHLPluriNASDAQ:PLURCortexymeNASDAQ:CRTXView All Competitors TVGN Stock Analysis - Frequently Asked Questions How have TVGN shares performed in 2024? Tevogen Bio's stock was trading at $9.51 on January 1st, 2024. Since then, TVGN shares have decreased by 89.5% and is now trading at $1.00. View the best growth stocks for 2024 here. How do I buy shares of Tevogen Bio? Shares of TVGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:TVGN) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressThe World's First "$20 Trillion Drug?"Behind the MarketsMan Who Predicted 2008: “This Will be Worse.”AltimetryJeff Bezos Just Humiliated Elon MuskInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tevogen Bio Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
